CORRIGENDUM

Chemotherapy Induces Ovarian Cancer Cell Repopulation Through the Caspase 3-Mediated Arachidonic Acid Metabolic Pathway [Corrigendum]

Cui LZ, Zhao YW, Pan Y, et al. Onco Targets Ther. 2017;10:5817-5826.

The authors have advised that there is an error in Figure 5A on page 5823. During figure assembly, the Magnification 10x images for panels Control and PF562271 were switched in error.

The correct Figure 5 is as follows.




Figure 5 The influence of the FAK inhibitor PF562271 (PF) on the VP-16-induced repopulation of SKOV3 cells. Notes: (A) Representative images of the crystal violet staining assay of the receptor cells with the FAK inhibitor PF562271 (PF) added to the system. (B) The stained cells of the four groups in A were solubilized with 1 mL of 33% acetic acid and quantified by the absorbance at 570 nm. The results are expressed as the mean ± SD of three independent experiments, n=3, *P<0.05 compared with the control group, $^{#}P$ <0.05 compared with the model group. Abbreviations: FAK, focal adhesion kinase; VP-16, etoposide phosphate; SD, standard deviation.

The authors apologise for this error and advise it does not affect the results of the paper.

For personal use only

Received: 15 November 2022 Accepted: 15 November 2022 Published: 5 December 2022

1503

CC 0 S C222 Cui et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.do /epress.com/terms.php you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S397709